By single-cell transcriptome analysis, a previous study (Ma et al., 2021) has revealed that EREG is predominantly expressed in macrophages in the TME and induces EGFR-tyrosine kinase inhibitor (TKI) resistance in the treatment of non-small cell lung cancer (NSCLC) by preventing apoptosis through the EGFR/ErbB2 heterodimer. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.